Tumor necrosis factor (TNF) blockers ignite FDA inquiry over cancer concerns.
Lindsley
Craig W
CW
Department of Pharmacology, Vanderbilt University, Vanderbilt University Medical Center, MRBIV, 12415D, Nashville, TN 37232-6600,USA.
D006801:Humans; D009369:Neoplasms / Q000378:metabolism*; D000079424:Tumor Necrosis Factor Inhibitors; D048069:Tumor Necrosis Factors / Q000378:metabolism; D014481:United States; D014486:United States Food and Drug Administration
D000079424:Tumor Necrosis Factor Inhibitors; D048069:Tumor Necrosis Factors